145 related articles for article (PubMed ID: 12499194)
1. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis.
Lefort A; Lafaurie M; Massias L; Petegnief Y; Saleh-Mghir A; Muller-Serieys C; Le Guludec D; Fantin B
Antimicrob Agents Chemother; 2003 Jan; 47(1):216-22. PubMed ID: 12499194
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis.
Murphy TM; Deitz JM; Petersen PJ; Mikels SM; Weiss WJ
Antimicrob Agents Chemother; 2000 Nov; 44(11):3022-7. PubMed ID: 11036017
[TBL] [Abstract][Full Text] [Related]
3. Activity of tigecycline (GAR-936), a novel glycylcycline, against Enterococci in the mouse peritonitis model.
Nannini EC; Pai SR; Singh KV; Murray BE
Antimicrob Agents Chemother; 2003 Feb; 47(2):529-32. PubMed ID: 12543654
[TBL] [Abstract][Full Text] [Related]
4. Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.
Saleh-Mghir A; Lefort A; Petegnief Y; Dautrey S; Vallois JM; Le Guludec D; Carbon C; Fantin B
Antimicrob Agents Chemother; 1999 Jan; 43(1):115-20. PubMed ID: 9869575
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci.
Vouillamoz J; Moreillon P; Giddey M; Entenza JM
J Antimicrob Chemother; 2006 Dec; 58(6):1208-14. PubMed ID: 17030515
[TBL] [Abstract][Full Text] [Related]
6. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia.
Edelstein PH; Weiss WJ; Edelstein MA
Antimicrob Agents Chemother; 2003 Feb; 47(2):533-40. PubMed ID: 12543655
[TBL] [Abstract][Full Text] [Related]
7. Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis.
Lefort A; Saleh-Mghir A; Garry L; Carbon C; Fantin B
Antimicrob Agents Chemother; 2000 Nov; 44(11):3017-21. PubMed ID: 11036016
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of tigecycline alone and in combination with gentamicin in the treatment of experimental endocarditis due to linezolid-resistant Enterococcus faecium.
Pontikis K; Pefanis A; Tsaganos T; Tzepi IM; Carrer DP; Giamarellou H
Antimicrob Agents Chemother; 2013 Jul; 57(7):3392-4. PubMed ID: 23587961
[TBL] [Abstract][Full Text] [Related]
9. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria.
van Ogtrop ML; Andes D; Stamstad TJ; Conklin B; Weiss WJ; Craig WA; Vesga O
Antimicrob Agents Chemother; 2000 Apr; 44(4):943-9. PubMed ID: 10722495
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination.
Mercier RC; Kennedy C; Meadows C
Pharmacotherapy; 2002 Dec; 22(12):1517-23. PubMed ID: 12495161
[TBL] [Abstract][Full Text] [Related]
11. Consequences of VanE-type resistance on efficacy of glycopeptides in vitro and in experimental endocarditis due to Enterococcus faecalis.
Lafaurie M; Perichon B; Lefort A; Carbon C; Courvalin P; Fantin B
Antimicrob Agents Chemother; 2001 Oct; 45(10):2826-30. PubMed ID: 11557476
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.
Sum PE; Petersen P
Bioorg Med Chem Lett; 1999 May; 9(10):1459-62. PubMed ID: 10360756
[TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent.
Projan SJ
Pharmacotherapy; 2000 Sep; 20(9 Pt 2):219S-223S; discussion 224S-228S. PubMed ID: 11001329
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of tigecycline: MICs, MBCs, time-kill curves and post-antibiotic effect.
Noviello S; Ianniello F; Leone S; Fiore M; Esposito S
J Chemother; 2008 Oct; 20(5):577-80. PubMed ID: 19028619
[TBL] [Abstract][Full Text] [Related]
15. The glycylcyclines: a comparative review with the tetracyclines.
Zhanel GG; Homenuik K; Nichol K; Noreddin A; Vercaigne L; Embil J; Gin A; Karlowsky JA; Hoban DJ
Drugs; 2004; 64(1):63-88. PubMed ID: 14723559
[TBL] [Abstract][Full Text] [Related]
16. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases.
Biedenbach DJ; Beach ML; Jones RN
Diagn Microbiol Infect Dis; 2001 Aug; 40(4):173-7. PubMed ID: 11576790
[TBL] [Abstract][Full Text] [Related]
17. Selection of glycopeptide-resistant mutants of VanB-type Enterococcus faecalis BM4281 in vitro and in experimental endocarditis.
Aslangul E; Baptista M; Fantin B; Depardieu F; Arthur M; Courvalin P; Carbon C
J Infect Dis; 1997 Mar; 175(3):598-605. PubMed ID: 9041331
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).
Petersen PJ; Jacobus NV; Weiss WJ; Sum PE; Testa RT
Antimicrob Agents Chemother; 1999 Apr; 43(4):738-44. PubMed ID: 10103174
[TBL] [Abstract][Full Text] [Related]
19. In vivo activities of evernimicin (SCH 27899) against vancomycin-susceptible and vancomycin-resistant enterococci in experimental endocarditis.
Souli M; Thauvin-Eliopoulos C; Eliopoulos GM
Antimicrob Agents Chemother; 2000 Oct; 44(10):2733-9. PubMed ID: 10991853
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.
Gales AC; Jones RN
Diagn Microbiol Infect Dis; 2000 Jan; 36(1):19-36. PubMed ID: 10744364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
